A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients.

Support Care Cancer · 2022 · PMC9213362 · PMID 35499619

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Infusion reactions were also numerically higher in the EMEND® group, but the difference did not reach statistical significance (OR = 4.35; 95%CI: 0.83 to 22.8).

also in 111,027 other papers

failed to reach statistical significanceno p-value reported

Over all cycles of chemotherapy, patients who received IV EMEND® had an increased risk of infusion site reactions compared to patients in the CINVANTI® group (OR = 4.35; 95%CI: 0.83 to 6.84), but the incremental risk failed to reach statistical significance, likely due to the small number of events (Table 6 ).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.